Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.

Neoplasia (New York, N.Y.) - 1 Jan 2011

Duignan Inga J, Corcoran Erik, Pennello Anthony, Plym Mary Jane, Amatulli Michael, Claros Nidia, Iacolina Michelle, Youssoufian Hagop, Witte Larry, Samakoglu Selda, Schwartz Jonathan, Surguladze David, Tonra James R

Abstract excerpt

The benefits of inhibiting vascular endothelial growth factor (VEGF) signaling in cancer patients are predominantly attributed to effects on tumor endothelial cells. Targeting non-endothelial stromal cells to further impact tumor cell growth and survival is being pursued through the inhibition of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hypoxia-Inducible Factor 1
Share to Lymphatic Vessels

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pericytes

Share to Pyrroles

Share to Stromal Cells

Share to Sunitinib

Share to Vascular Endothelial Growth Factor Receptor-2

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 21245940
DOI: 10.1593/neo.101162
PMCID: PMC3022428

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21245940-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.PMID 21245940Read ↗

Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.Semantic proximity Read ↗

Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.Semantic proximity Read ↗

Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.Semantic proximity Read ↗

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.Semantic proximity Read ↗

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell CarcinomaSemantic proximity Read ↗

Targeting renal cell carcinoma with a HIF-2 antagonist.Semantic proximity Read ↗

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.Semantic proximity Read ↗

Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype.Semantic proximity Read ↗

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.Semantic proximity Read ↗

Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.